Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JENCYCLA vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Treatment of urea cycle disorders involving deficiencies of carbamoyl phosphate synthetase 1, ornithine transcarbamylase, or argininosuccinic acid synthetase,Treatment of primary biliary cholangitis (off-label)
Prevention of pregnancy
1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
8-12 hours; prolonged to 24 hours in severe hepatic impairment
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Sodium phenylbutyrate is metabolized via beta-oxidation to phenylacetate, which conjugates with glutamine. Ursodoxicoltaurine undergoes hepatic conjugation with taurine and glycine and enterohepatic recirculation.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal: 35-45% unchanged; biliary/fecal: 50-60% as metabolites
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
92-96% bound to albumin and alpha-1-acid glycoprotein
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
3.5-5.0 L/kg; indicates extensive tissue distribution
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 75-90%; IV: 100%
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
GFR 30-50 m L/min: reduce dose by 50%. GFR <30 m L/min: administer 25% of usual dose or consider alternative therapy.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
0.5-1 mg/kg IV every 3-4 weeks; not established for weight <10 kg.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
No specific dose adjustment; monitor renal function and consider starting at lower end of dosing range due to age-related decline in renal function.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
None
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Neurotoxicity due to phenylacetate accumulation (monitor neurologic status); pancreatic insufficiency; hyperammonemic encephalopathy; fluid overload; electrolyte disturbances; hepatotoxicity; hypersensitivity reactions; gastrointestinal disorders.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Hypersensitivity to sodium phenylbutyrate, ursodoxicoltaurine, or any component; complete biliary obstruction; acute cholecystitis; severe hepatic impairment (Child-Pugh C).
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
Avoid grapefruit and grapefruit juice as they may increase estrogen levels and risk of side effects. No specific food restrictions; however, high-fat meals may increase absorption variability. Consistent intake with or without food is recommended.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
JENCYCLA (asciminib) is not recommended during pregnancy. Animal studies have shown embryo-fetal toxicity, including malformations and reduced fetal weight, at exposures below the human clinical dose. There are no adequate human studies. Use effective contraception during treatment and for at least 1 week after the last dose. First trimester: Potential for major congenital anomalies. Second and third trimesters: Risk of fetal growth restriction and adverse effects on fetal development.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
It is unknown if JENCYCLA is excreted in human milk. Animal studies indicate excretion in milk. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 1 week after the last dose. M/P ratio: not determined.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
No specific dosing adjustments in pregnancy are established due to lack of data. However, physiological changes in pregnancy (e.g., increased volume of distribution, renal clearance) may alter pharmacokinetics. Use only if benefit outweighs risk; if used, monitor therapeutic drug levels and clinical response for potential dose adjustments. Not recommended during pregnancy.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
JENCYCLA (norethindrone/ethinyl estradiol) is a combined oral contraceptive; counsel patients to take at the same time daily to maintain consistent hormone levels and maximize efficacy. Advise use of backup contraception during the first 7 days of therapy. Be aware of increased risk of venous thromboembolism, especially in smokers over 35 years of age. Monitor for breakthrough bleeding; if it persists beyond 3 cycles, consider alternative formulation.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one tablet daily at the same time, preferably with food to reduce nausea.,If you miss a dose, refer to the package insert instructions; consider backup contraception if needed.,Common side effects include nausea, breast tenderness, and spotting; these often improve within a few cycles.,Seek immediate medical attention for leg pain/swelling, chest pain, shortness of breath, or severe headache.,Do not smoke while taking this medication, especially if over 35 years old.,This medication does not protect against sexually transmitted infections (STIs).
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JENCYCLA vs ALYACEN 7/7/7, answered by our medical review team.
JENCYCLA is a Oral Contraceptive that works by JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JENCYCLA and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JENCYCLA is: 1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JENCYCLA and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JENCYCLA is classified as Category C. JENCYCLA (asciminib) is not recommended during pregnancy. Animal studies have shown embryo-fetal toxicity, including malformations and reduced fetal weight, at exposures below the . ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.